Specific guidance in the HIV-infected population was not previously available, partly because persons living with HIV were previously excluded from cancer clinical trials, creating a knowledge gap.
Treatment with crizotinib elicited an objective response rate of 50% for patients with ALK-positive advanced, inoperable inflammatory myofibroblastic tumor.
Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion–positive solid tumors, according to updated results for the novel pan-TRK inhibitor.
Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Adjuvant therapy, regardless of the treatment modality, did not improve overall survival compared with observation for women with early stage, uterine-confined leiomyosarcoma.
Although second-line treatment with combined pazopanib and gemcitabine demonstrated disease control in the majority of patients with metastatic or relapsed uterine or soft tissue leiomyosarcomas, the phase II UNICANCER SARCOME 11 study did not meet statistical endpoints and is considered a negative trial.
Neeta Somaiah, MD, discusses the efficacy of CMB305 in patients with synovial sarcoma or myxoid/round cell liposarcoma.
Long-term follow-up showed that trabectedin (Yondelis) was associated with high rates of survival and clinical benefit rate for patients with advanced high grade soft tissue sarcomas.
Cediranib was associated with significantly reduced tumor burden and superior progression-free survival compared with placebo in patients with alveolar soft part sarcoma.
As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.